Free tools Windows power users keep installed
One-click scans. No signup required.
iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
Researchers have engineered an enzyme called Brec1 to target and excise integrated HIV-1 DNA in laboratory and animal studies. That is not the same as curing AIDS, and the evidence does not show that Brec1—or another gene-editing approach—has cured HIV in people. These experiments target HIV-1 proviral DNA, not “AIDS DNA”: AIDS is the advanced clinical syndrome associated with HIV infection.
Why researchers are trying to remove HIV DNA
Combination antiretroviral therapy (ART) can suppress HIV reproduction, but HIV-1 can persist as proviral DNA integrated into the DNA of infected cells. That persistent reservoir is one reason suppressing the virus is different from eliminating it.
One proposed strategy is to target and remove proviral DNA from cells. Brec1 is an engineered recombinase developed for that purpose. It is distinct from CRISPR-based approaches, which use a guide RNA to direct a DNA-cutting enzyme to a target.
Recommended Free Tools
What Brec1 is designed to do
In a 2016 study, Karpinski and colleagues used 145 cycles of substrate-linked directed evolution to develop Brec1. The resulting recombinase recognizes a 34-base-pair sequence in HIV-1 long terminal repeats (LTRs). Because LTRs flank the integrated provirus, the intended strategy is to recombine those sites and excise the intervening viral DNA.
#1 Best Overall
The researchers reported activity against a majority of clinically relevant HIV-1 strains and subtypes, and tested Brec1 in infected cells, clinical isolates and humanized mice. Those results establish experimental activity in the systems studied; they do not establish a treatment that works in people.
How Brec1 differs from CRISPR
| Approach | How it targets HIV DNA | Reported evidence and limits |
|---|---|---|
| Brec1 recombinase | An engineered recombinase recognizes a 34-base-pair sequence in HIV-1 LTRs and is intended to join the target sites to excise the intervening proviral DNA. | The 2016 study reported cell, clinical-isolate and humanized-mouse experiments. These are not human cure results. |
| CRISPR/Cas9 and related systems | A guide RNA directs a nuclease to selected HIV DNA sequences, where the DNA can be cut. The resulting repair may produce excision or other outcomes, including mutations. | Separate studies have reported cell and animal experiments. The results depend on the guides, delivery method and how the edited DNA is measured; they are not evidence of an established cure. |
The approaches should not be conflated: Brec1 is not CRISPR, and the CRISPR studies described below do not demonstrate Brec1’s mechanism or effectiveness. The available studies also do not provide a head-to-head clinical comparison.
Rank #2
What the CRISPR studies add—and what they do not
A separate 2016 proof-of-concept study used SaCas9 with multiple guide RNAs directed at HIV DNA. After delivery with an AAV9 vector, the authors reported excision of a 978-base-pair fragment in transgenic mice and a reduction in a targeted viral DNA segment in transgenic rats. These were animal experiments using CRISPR, not tests of Brec1 in people.
Quick wins for a faster PC:
Scan for outdated or missing drivers - takes under a minuteDriver Scan →Clear out junk files and repair common Windows errorsFree Scan →A 2019 humanized-mouse study reported that sequential LASER ART followed by CRISPR-Cas9 left no detectable virus in several tested tissues in a subset of animals. In that experiment, neither treatment alone produced that result. This is an animal-model finding; it does not establish that the combination cures HIV in humans.
Rank #3
Why excision is not the same as eliminating the reservoir
DNA left behind after editing
Cutting or recombining viral DNA does not guarantee that every edited product is harmless or permanently gone. A CRISPR/Cas9 excision study reported that excised proviral DNA could persist for weeks as circular molecules. Some circles had restored LTRs and could be transcriptionally active in the presence of Tat and Rev. The authors discussed ways to limit residual activity and reintegration risk.
Unexpected editing and repair outcomes
Another publication reported large unintended deletions after CRISPR-Cas attack on HIV proviral DNA, including deletions that could encompass surrounding cellular DNA. A separate dual-guide study found that, under the conditions tested, target-site mutation occurred more often than fragment excision; results varied with the guide combination. These are experimental safety concerns, not quantified estimates of risk to patients.
Rank #4
- New
- Mint Condition
- Dispatch same day for order received before 12 noon
- Guaranteed packaging
- No quibbles returns
Why the measurement method matters
A 2026 paper on SaCas9 editing compared single- and dual-guide strategies and noted that PCR-based detection can favor amplification of shorter excision products over other outcomes. An apparent increase in excision products therefore needs to be interpreted in light of what the assay can detect, including mutations, larger rearrangements and other repair products.
Delivery to the cells that harbor HIV
Even a precise editing system has to reach the relevant infected cells, including cells with latent HIV. An NIH-funded project record describes research to deliver Cas12a ribonucleoprotein or messenger RNA to CD4-expressing cells over a performance period of December 1, 2022, through November 30, 2027. That record describes a research objective, not a clinically successful delivery platform.
Best Value
Delivery is therefore a separate hurdle from designing an enzyme or guide sequence: reaching some cells in a laboratory or animal model does not show that a therapy can safely and efficiently reach the full range of reservoir cells in a person.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What is known about clinical testing
A California Institute for Regenerative Medicine award record describes EBT-101 as an investigational, single-dose gene therapy using an AAV9 vector carrying HIV-specific CRISPR/Cas9 guide sequences. The stated study objectives include assessing safety, biodistribution and excision. The award record is marked closed; it is not a current trial-status check and does not establish efficacy, approval or cure. EBT-101 is a CRISPR-based program, not Brec1.
In short, the evidence described here spans laboratory and animal studies, alongside a record describing an investigational clinical program. It does not show that an engineered enzyme has cured HIV in people.
Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchWindows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallCan Brec1 or CRISPR replace ART?
No evidence here supports replacing or stopping prescribed antiretroviral therapy. These editing approaches remain experimental, and the studies described do not establish that they can eliminate HIV from a person. Do not change treatment based on findings from cell or animal research; discuss treatment decisions with a qualified healthcare professional.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
